Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2026
Reporting Period: First Quarter ended March 31, 2026
This filing announces the release of the Company's results of operations and financial condition for the first quarter of 2026. The detailed financial data is contained in a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), which are incorporated by reference but not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The filing text does not provide specific numerical values for revenue, net income, operating cash flow, margins, debt levels, or liquidity positions. These figures are referenced as being available in the attached press release and presentation exhibits, which are not included in the provided text.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data to compare current quarter performance against prior comparable periods. Investors must refer to the referenced press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
- Management Commentary: The Company released an updated corporate presentation to its investor website on May 6, 2026.
- Forward-Looking Statements: The report contains forward-looking statements regarding anticipated performance under the "Tempus Agreement" and the "Restated Agreement."
- Risks and Uncertainties: Management cautions that actual results may differ materially from projections due to known and unknown risks. Specific risk factors are detailed in the Company's most recent Form 10-K and subsequent Form 10-Q filings.
- Unusual Items: No unusual items are explicitly detailed in the text of this 8-K summary.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash burn figures.
- Examine Exhibit 99.2 (Earnings Presentation) for updated operational milestones and pipeline progress.
- Verify the status and terms of the Tempus Agreement and Restated Agreement mentioned in the forward-looking statements.
- Consult the most recent Form 10-K and Form 10-Q for a comprehensive list of risk factors affecting the business.